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Abstract
Background: JAMA introduced a requirement for independent statistical analysis for industry-funded trials in July 2005. We
wanted to see whether this policy affected the number of industry-funded trials published by JAMA.
Methods and Findings: We undertook a retrospective, before-and-after study of published papers. Two investigators
independently extracted data from all issues of JAMA published between 1 July 2002 and 30 June 2008 (i.e., three years
before and after the policy). They were not blinded to publication date. The randomized controlled trials (RCTs) were
classified as industry funded (IF), joint industry/non-commercial funding (J), industry supported (IS) (when manufacturers
provided materials only), non-commercial (N) or funding not stated (NS). Findings were compared and discrepancies
resolved by discussion or further analysis of the reports. RCTs published in The Lancet and NEJM over the same period were
used as a control group. Between July 2002 and July 2008, JAMA published 1,314 papers, of which 311 were RCTs. The
number of industry studies (IF, J or IS) fell significantly after the policy (p=0.02) especially for categories J and IS. However,
over the same period, the number of industry studies rose in both The Lancet and NEJM.
Conclusions: After the requirement for independent statistical analysis for industry-funded studies, JAMA published
significantly fewer RCTs and significantly fewer industry-funded RCTs. This pattern was not seen in the control journals. This
suggests the JAMA policy affected the number of submissions, the acceptance rate, or both. Without analysing the
submissions, we cannot check these hypotheses but, assuming the number of published papers is related to the number
submitted, our findings suggest that JAMA’s policy may have resulted in a significant reduction in the number of industry-
sponsored trials it received and published.
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Introduction
In July 2005, JAMA (the Journal of the American Medical
Association) introduced a requirement that industry-sponsored
studies must undergo independent analysis by statisticians at
academic institutions [1]. This policy has not been adopted by
other medical journals and, in fact, has been criticised by some
statisticians [2]. When the policy was introduced, it was
rumoured that some pharmaceutical companies would boycott
JAMA and refuse to submit papers there. We therefore wanted to
see whether the requirement for independent statistical analysis
was associated with any change in the number of industry-
sponsored studies published in JAMA. We therefore compared
the number of industry-sponsored studies published in JAMA
before and after the policy was introduced and used papers
published in two other high impact, general, medical journals as
a control.
Methods
Two investigators independently coded all randomized con-
trolled trials (RCTs) published in JAMA from 1 July 2002 to 30
June 2008 (i.e., 3 years before and after the policy was introduced).
The investigators were not blinded to publication date. RCTs
were identified from article titles (in the journal’s electronic tables
of contents) and inspection of the methods (if in doubt). Electronic
versions (PDFs) of all RCTs were downloaded from the journal’s
website and their funding determined. Trials were classified as:
industry funded (IF), joint industry plus non-commercial funding
(J), industry supported (IS) (when manufacturers provided
materials only but had no input into research design or execution),
non-commercial (N) or funding not stated (NS). For the statistical
analysis, RCTs were classified a priori as ‘Industry’ if they had any
commercial funding or support (i.e., we considered all those in the
IF, J and IS categories as ‘Industry’ studies). RCTs published in
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same period provided the control (as these journals did not change
their requirements). The same methods of retrieval and catego-
rization were used for JAMA and the control journals. In all cases,
discrepancies were resolved by discussion or further analysis until
consensus was achieved.
Results
The total number of RCTs published in JAMA decreased
significantly after July 2005 but increased in NEJM and remained
stable in The Lancet (Table 1, Figure 1). The proportion of Industry
RCTs also decreased significantly in JAMA, but rose significantly
in both NEJM and The Lancet over the same period.
Further categorization to distinguish trials funded completely by
industry (IF) from those with joint funding (J) or those for which
companies provided support (i.e. drugs or equipment) but took no part
in design or analysis (IS) showed a more complex pattern. All
categories of Industry studies (IF, IS and J) decreased in JAMA,w h i l e
in NEJM, IF and IS increased while J remained stable, and in Lancet IF
increased markedly but IS decreased and J remained stable (Table 1).
The number of reports with no funding source stated, or for
which the investigators, despite their experience in the area, had
difficulty determining the nature of the funding source was notable
(32 articles altogether in the three journals) although the actual
proportion was small (2.6%). While caution should be exercised in
interpreting such small numbers, it appeared that JAMA had a
lower proportion of RCTs with unstated or unclear funding than
the other journals (5 in JAMA,1 4i nNEJM,1 3i nLancet).
Although JAMA announced its policy in July 2005, we could not
tell exactly when it started to take effect (since several months
usually elapse between submission and publication of articles). We
therefore conducted a sensitivity analysis to measure the effect of
the articles published between July and December 2005. During
this (possible transition) period, JAMA published 19 RCTs. If these
are excluded from the analysis, our findings are unchanged and we
still observe significantly fewer Industry RCTs in the period
following the new policy (p=0.02).
Discussion
The proportion of industry-sponsored studies published in
JAMA decreased significantly after the journal required indepen-
dent statistical analysis but increased in the two control journals
over the same period. While our study cannot explain the
underlying causes, we suggest that the most plausible explanation
for our findings is that there is a finite number of high-impact
general journals in which industry wants to publish RCTs so a
policy in one journal may result in a ‘zero-sum game’: if fewer
RCTs are published in JAMA then more are published in NEJM
and Lancet (or elsewhere). However, our findings may, instead, be
due to other causes, such as policies at Lancet and/or NEJM to
publish more industry-funded studies, or other more general
trends in funding patterns or publication affecting the proportion
of industry-funded studies being published. One surprising aspect
of our findings was that the number of industry-supported studies
and jointly funded studies published by JAMA decreased to a
similar extent as solely industry-funded studies, despite the fact
that such studies are generally analysed by academic statisticians
and might therefore be expected to be unaffected by the policy
requirements.
Since we could analyse only published trials, we cannot tell
whether the policy affected submission or acceptance rates.
However, according to the journal, the total number of
submissions to JAMA rose steadily between 2002 and 2005 (from
4615 to 5744 per year) then fell in 2006 to 5354, rose to 5551 in
2007 and fell slightly to 5525 in 2008 [3].
We requested information from JAMA on acceptance rates
according to funding source but were informed that these were not
available. However, it seems reasonable to assume that the
number of published papers is probably related to the number
submitted, and, given the overall fall in the number of submissions,
and the rumours of an industry ‘boycott’ of JAMA, this is
consistent with a decrease in the number of industry-sponsored
trials being submitted to JAMA at least in the years immediately
following the introduction of the policy.
JAMA’s policy has not been adopted by other major journals
and has been criticised by some statisticians [2]. We did not
attempt to measure the quality of the published papers (and, in
particular their statistical methods) to see if this had changed. It
would also be interesting to discover what, if any, changes, the
independent statistical reviewers suggested.
The key question is whether JAMA’s policy protected its readers
by publishing more reliable trial reports. We cannot tell if the
policy has improved the standard of reporting but it was associated
with a significant decrease in the number of industry-sponsored
Table 1. Number of randomized trials (RCTs) and studies with commercial funding published in JAMA, NEJM and The Lancet in the









All papers 677 637 616 606 530 529
RCTs (%) 178 (26) 133 (21) 258 (42) 276 (46) 199 (38) 210 (40)
p-value 0.02 0.20 0.48
Industry
3 (%) 107 (63) 63 (37) 155 (44) 196 (56) 106 (45) 129 (55)
p-value 0.01 0.03 0.01
IF, IS, J
4 49, 35, 23 39, 19, 5 82, 26, 47 102, 44, 50 47, 30, 29 79, 18, 32
RCTs with funding not stated/unclear 2 3 10 4 7 6
11 July 2002–30 June 2005.
21 July 2005–30 June 2008.
3Studies with any commercial funding.
4IF = solely industry funded, IS = industry support (drugs or equipment only), J = jointly funded by industry and non-commercial sources.
doi:10.1371/journal.pone.0013591.t001
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two other high-ranking general medical journals. To the extent
that one associates industry sponsorship with increased risk for
biased reporting [4] one can argue that the policy may have
achieved its desired results at least within JAMA. However, if it
simply had the effect of deflecting reports of industry-funded
studies from a journal with a more-demanding policy (ie JAMA)t o
journals with less-demanding policies, then the overall effect on the
literature would have been minimal.
Author Contributions
Conceived and designed the experiments: EW BD. Performed the
experiments: EW RM SW BD. Analyzed the data: RM BD. Wrote the
paper: EW BD. Reviewed the paper: RM.
References
1. Fontanarosa PB, Flanagin A, DeAngelis CD (2005) Reporting conflicts of
interest, financial aspects of research and role of sponsors in funded studies.
JAMA 294: 110–111.
2. Rothman KJ, Evans S (2005) Extra scrutiny for industry funded trials. BMJ 331:
1350–1351.
3. Fontanarosa PB, DeAngelis C (2009) Thank you, JAMA peer reviewers and
authors. JAMA 301: 870.
4. Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry
sponsorship and research outcome and quality: systematic review. BMJ 326:
1167–1170.
Figure 1. Number of randomized controlled trials published by (a) JAMA, (b) NEJM and (c) Lancet by funding source over time. (JAMA
introduced its policy for independent statistical analysis for industry-funded studies in July 2005.) ‘Industry’ funded trials includes those that were:
solely industry funded; jointly funded by industry and non-commercial sources; or supported by the industry (i.e. the manufacturer provided
materials only).
doi:10.1371/journal.pone.0013591.g001
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